Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Fig. 2

CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live singlet lymphocytes, CD3CD56CD19low/midCD20CD38hiCD27hiCD138+. Plasmablasts are gated as live singlet lymphocytes, CD3CD56CD19low/midCD20CD38hiCD27hiCD138. CD19hi B cells are separated into naïve B cell (IgD+CD27), non-class-switched memory B cell (CD27+IgD+), class-switched memory B cell (CD27+IgD) and CD27 memory B cell (CD27IgD). b Percentage of CD27hiCD38hiCD138+ plasma cells in total lymphocytes from PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27hiCD38hiCD138 plasmablasts in total lymphocytes from PBMCs from different groups. d-f Percentage of class-switched memory cell (d), CD27 memory B cell (e), and non-class-switched memory B cell (f) in total lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27 memory cell, plasma cells and plasmablasts

Back to article page